Development and temporal evaluation of sex-specific models to predict 4-year atherosclerotic cardiovascular disease risk based on age and neighbourhood characteristics in South Limburg, the Netherlands

在荷兰南林堡地区,基于年龄和居住地特征,开发并进行性别特异性模型的时间评估,以预测4年动脉粥样硬化性心血管疾病风险。

阅读:1

Abstract

BACKGROUND: To improve screening for atherosclerotic cardiovascular disease (ASCVD), we aimed to develop and temporally evaluate sex-specific models to predict 4-year ASCVD risk in South Limburg based on age and neighbourhood characteristics concerning home address. METHODS: We included 40- to 70-year-olds living in South Limburg on 1 January 2015 for model development, and 40- to 70-year-olds living in South Limburg on 1 January 2016 for model evaluation. We randomly sampled people selected in 1 year and in both years to create development and evaluation data sets. Follow-up of ASCVD and competing events (overall mortality excluding ASCVD) lasted until 31 December 2020. Candidate predictors were the individual's age, the neighbourhood's socio-economic status, and the neighbourhood's particulate matter concentration. Using the evaluation data sets, we compared two model types, subdistribution and cause-specific hazard models, and eight model structures. Discrimination was assessed by the area under the receiver operating characteristic curve (AUROC). Calibration was assessed by calculating overall expected-observed ratios (E/O). For the final models, calibration plots were made additionally. RESULTS: The development data sets consisted of 67,549 males (4-year cumulative ASCVD incidence: 3.08%) and 67,947 females (4-year cumulative ASCVD incidence: 1.50%). The evaluation data sets consisted of 66,068 males (4-year cumulative ASCVD incidence: 3.22%) and 66,231 females (4-year cumulative ASCVD incidence: 1.49%). For males, the AUROC of the final model equalled 0.6548. The E/O equalled 0.9466. For females, the AUROC equalled 0.6744. The E/O equalled 0.9838. CONCLUSIONS: The resulting model shows promise for further research. These models may be used for ASCVD screening in the future.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。